BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38051221)

  • 41. Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
    Conn E; Hour S; Allegakoen D; Graham G; Petro J; Kouassi-Brou M; Hong SH; Selvanathan S; Çelik H; Toretsky J; Üren A
    Mol Med Rep; 2020 Mar; 21(3):1667-1675. PubMed ID: 32016454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
    Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
    Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.
    Çelik H; Sciandra M; Flashner B; Gelmez E; Kayraklıoğlu N; Allegakoen DV; Petro JR; Conn EJ; Hour S; Han J; Oktay L; Tiwari PB; Hayran M; Harris BT; Manara MC; Toretsky JA; Scotlandi K; Üren A
    Oncogene; 2018 Apr; 37(16):2181-2196. PubMed ID: 29382926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
    Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
    Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
    Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
    Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases.
    Jimenez RE; Folpe AL; Lapham RL; Ro JY; O'Shea PA; Weiss SW; Amin MB
    Am J Surg Pathol; 2002 Mar; 26(3):320-7. PubMed ID: 11859203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
    Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
    Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RUNX3 facilitates growth of Ewing sarcoma cells.
    Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
    J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
    Heitzeneder S; Sotillo E; Shern JF; Sindiri S; Xu P; Jones R; Pollak M; Noer PR; Lorette J; Fazli L; Alag A; Meltzer P; Lau C; Conover CA; Oxvig C; Sorensen PH; Maris JM; Khan J; Mackall CL
    J Natl Cancer Inst; 2019 Sep; 111(9):970-982. PubMed ID: 30698726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
    Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
    Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
    Zhou Z; Yu L; Kleinerman ES
    Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetically Engineered Mouse Model in Ewing Sarcoma.
    Tanaka M; Nakamura T
    Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.